## WE CLAIM:

- 1. A composition comprising a core containing a pharmaceutically active agent wherein the core is encapsulated with a membrane comprising esterified  $C_{12}$ - $C_{18}$  fatty acids wherein the concentration of fatty acids in the composition is less than 15 weight %.
- 2. The composition of Claim 1 wherein the core is a microemulsion or liposome.
- 3. The composition of Claim 2 wherein the microemulsion contains a phospholipid and a surfactant.
- 4. The composition of Claim 2 wherein the lipsome contains a hydrophilic phase containing the pharmaceutically active agent and a continuous hydrophilic phase containing cholesterol, phospholipid, lipophilic surfactant and unesterified fatty acid.
- 5. The composition of Claim 1 wherein the pharmaceutically active agent is insulin, growth hormone, interferon, calcitonin, urokinase, coagulation Factor-VIII, coagulation Factor IX, erythroporetin, nafcillin, vincristin, cephazoline, doxorubicin, quinine, chloroquine, primaquine, d-alpha-tocophenol, gentamicin, glyburide, indomethacin, oxyphenbutazone, chlorothiazole, propranolol, cyclophosphamide, physostigmine, fluoxetine or feldene.
- 6. The composition of Claim 1 wherein the pharmaceutically active agent is insulin.

- 7. The composition of Claim 1 wherein the  $C_{12}$ - $C_{18}$  fatty acids are extracted from coconut.
- 8. The composition of Claim 1 wherein the membrane is about 0.02mm thick.
- 9. The composition of Claim 1 wherein the membrane is further encapsulated with a film coating.
- 10. The composition of Claim 9 wherein the film coating comprises gelatin.
- 11. The composition of Claim 9 which is a minicapsule having a diameter of about 1.8 to 3.0 millimeters.
- 12. The composition of Claim 11 which is further coated with an enteric coating.
- 13. A method of making a composition comprising a pharmaceutically active agent comprising the steps of:
- (a) providing a liposome or microemulsion containing a pharmaceutically active agent;
- (b) coating the liposome or microemulsion with a mid-layer comprising esterified  $C_{12}$ - $C_{18}$  saturated fatty acids;
  - (c) coating said midlayer with a film layer to provide a minicapsule.
- 14. The method of Claim 13 further comprising the step of capsulating said minicapsule into a gelatin capsule.

15. The method of Claim 13 wherein said lipsome or microemulsion is in dry powder form.

- 16. The method of Claim 13 wherein said minicapsule has a diameter of from about 1.8 to 3.0 millimeters.
- 17. A method of delivering a pharmaceutically active agent to a mammal comprising orally administering the composition of Claim 1 to said mammal.
- 18. The method of Claim 17 wherein said mammal is a human.